Article
Nov 12, 2025

Improving Biological Age with GLP-1 RAs: An Analysis of a Study 

This is a further dive into and expansion of a Journal Club video that I offered in September 2025 in response to a fascinating article related to the power of GLP-1 peptides to create positive epigenetic changes at the cellular level. 

The study, Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial, is in preprint and has not yet been peer-reviewed, but offers substantive evidence of semaglutide’s versatile effects on cellular pathways related to metabolism, inflammation, and the immune system. In particular, the study examines the use of semaglutide (a GLP-1 receptor agonist) to control or slow the epigenetic aging of people with HIV (PWH) and  associated lipohypertrophy, a common condition with this population of patients. 

Through the lens of “the emerging geroscience paradigm” (Kennedy,et al, 2014), the study authors suggest that HIV-associated lipohypertrophy (a condition characterized by excessive accumulation of visceral and ectopic adipose tissue) offers an opportunity to examine the impact of semaglutide on a cohort who represent the “accelerated-aging phenotype” and look at possible implications for GLP-1 RAs as agents that improve biological age.

I was drawn to this article because of its focus on the pleiotropic power of GLP-1 RAs, a topic that I’ve discussed in several Masterminds, focused on in my soon-to-be released weight loss course, and devoted an entire book to – The Quantum Power of GLP-1 Peptides (SSRP, 2025). As we know from the plethora of existing research, GLP-1 peptides such as Semaglutide decrease inflammation, improve metabolism, and support the immune system. The two-part question that the article prompted for me was this: if GLP-1 RAs can positively affect cellular metabolism, immune function, and inflammation, thereby altering the cellular environment, wouldn’t it make sense that they also have the potential to increase the healthspan – or lifespan – of the cell? And I think the answer, intuitively, is – absolutely.  

Members-Only Content

This article contains exclusive content for SSRP members. Join today to unlock the full article and gain access to our entire library of resources.

Unlock Full Article
RELATED RESOURCES

Continue exploring related topics.

VIEW ALL
SSRP Institute Sep 14, 2026
In Case You Missed it: FDA Approves Mounjaro (tirzepatide) for CVD
HEADLINE SCIENCE [Sept 14, 2026] – On August 28, 2026, the FDA expanded the indication for Mounjaro (tirzepatide), approving the dual GIP/GLP-1 receptor agonist to reduce the risk of major adverse cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in adults with type 2 diabetes at high cardiovascular risk. The decision makes tirzepatide the […]
READ NEWS
EVENT
Certification
September 10 - 11, 2027
Peptide Therapy Certification 2027
Four Seasons Resort Orlando at Walt Disney World, FL
COMING SOON
Certification
Peptide Therapy Certification 2027
COMING SOON
EVENT
World Congress
June 17 - 19, 2027
Peptide World Congress 2027
Arizona Biltmore, Phoenix, AZ
COMING SOON
World Congress
Peptide World Congress 2027
COMING SOON
EVENT
Mastermind
February 15 - 19, 2027
Fellowship Mastermind Summit 2027
Gansevoort Meatpacking NYC, New York, NY
COMING SOON
Mastermind
Fellowship Mastermind Summit 2027
COMING SOON
EVENT
Grand Rounds
December 4 - 5, 2026
Grand Rounds
Four Seasons Resort and Residences Vail
COMING SOON
Grand Rounds
Grand Rounds
COMING SOON
VIDEO
Cellular Medicine Mondays
Sep 14, 2026
Ep. 105 - Dr. Seeds’ Office Hours
Preview Only
VIDEO
Cellular Medicine Mondays
Sep 7, 2026
Ep. 104 - Phenotyping is Essential to Cellular Medicine
Preview Only
Rabbit Holes – Episode 104

Phenotyping is Essential to Cellular Medicine

In this episode of Rabbit Holes, Dr. Seeds breaks down why phenotyping is essential to Cellular Medicine. Understanding the individual patient allows for more precise, personalized care instead of guessing or relying on random peptide protocols.

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Aug 31, 2026
Ep. 103 - Liposomal Peptides
Preview Only
Dissecting Protocols – Episode 103

Liposomal Peptides

Dr. Seeds takes a closer look at liposomal peptides, including Epitalon, BPC-157, TB4, KPV, and GHK-Cu, and examines the claims around sourcing, stability, absorption, bioavailability, injection fatigue, and whether these formulations can truly compare to injectable peptides.

Preview Only — Become a member for full access
SSRP Institute Aug 27, 2026
Rasonque: An FDA-Approved Drug to Treat Pancreatic Cancer
HEADLINE SCIENCE [August 27, 2026] – The Food and Drug Administration on Wednesday approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer and one long considered among the hardest to treat. The once-daily tablet, developed by Revolution Medicines, is the first targeted therapy approved for the […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Aug 24, 2026
Ep. 102 - Office Hours: PWC26 Virtual Summit Part 4
Preview Only
Office Hours PWC26 Virtual Summit Part 4 – Episode 102

Office Hours PWC26 Virtual Summit Part 4- Episode 102

  1. Compounded topical creams and GHK-Cu with microneedling (0:59)
  2. Detoxing before using copper (12:09)
  3. Patient onboarding process (12:54)
  4. Zinc and iron supplementation with GHK-Cu (23:41)
  5. Loss of taste after COVID (25:55)
  6. 3D CT scans for root canals (27:03)
  7. Oral bacteria swabs and GLP-1 effectiveness (28:00)
  8. Endocannabinoid system (29:07)
  9. GHK-Cu efficacy on wound beds (32:05)

Preview Only — Become a member for full access

Subscribe to the SSRP Community Digest

Get the latest research and developments in the field of Cellular Medicine straight to your inbox every month.

This field is for validation purposes and should be left unchanged.